



CLAIMS

1. A compound of Formula (1):



5 or a pharmaceutically acceptable salt thereof, wherein:

Ring Q¹ is Formula (2):



wherein Ring Q³ is a 5- or 6-membered aromatic heterocyclic ring;

10 wherein the 5- or 6-membered aromatic heterocyclic ring is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, NH₂, OH, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl;

15 wherein each C₁₋₆ alkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and OC₁₋₆ alkyl;

20 wherein each NH₂ substituent of Ring Q³ is optionally and independently substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents;

wherein each OC₁₋₆ alkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and a saturated 4- to 8-membered heterocyclyl; and

wherein each C₃₋₁₀ cycloalkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

W is CR^{C^D};

10 X is -CH₂-;


Y is N;

m is 0;

bond (b) is a single bond; and

~~~~ is the point of attachment to V;

15 Ring Q<sup>2</sup> is Formula (3a) or Formula (3b):



wherein

~~~~ is the point of attachment to Z;

each V is independently -CR^{A^B}-;

20 Z is C, CR^J, or N;

R^{1a} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1b} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1c} is hydrogen, halogen, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1, 2, or 3

independently selected halogen substituents;

R^{1d} is hydrogen, halogen, or C_{1-6} alkyl, wherein the C_{1-6} alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

5 R^{2a} is hydrogen, halogen, cyano, C_{1-6} alkyl, NH_2 , or OC_{1-6} alkyl;

wherein the C_{1-6} alkyl or OC_{1-6} alkyl of R^{2a} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

10 wherein the NH_2 of R^{2a} is optionally substituted with 1 or 2 independently selected C_{1-6} alkyl substituents;

R^{2b} is hydrogen, halogen, cyano, C_{1-6} alkyl, NH_2 , or OC_{1-6} alkyl;

15 wherein the C_{1-6} alkyl or OC_{1-6} alkyl of R^{2b} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH_2 of R^{2b} is optionally substituted with 1 or 2 independently selected C_{1-6} alkyl substituents;

20 R^{2c} is hydrogen, halogen, cyano, C_{1-6} alkyl, NH_2 , or OC_{1-6} alkyl;

wherein the C_{1-6} alkyl or OC_{1-6} alkyl of R^{2c} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

25 wherein the NH_2 of R^{2c} is optionally substituted with 1 or 2 independently selected C_{1-6} alkyl substituents;

R^{2d} is hydrogen, halogen, cyano, C_{1-6} alkyl, NH_2 , or OC_{1-6} alkyl;

30 wherein the C_{1-6} alkyl or OC_{1-6} alkyl of R^{2d} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

wherein the NH_2 of R^{2d} is optionally substituted with 1 or 2 independently selected C_{1-6} alkyl substituents;

each R^A is independently hydrogen, C_{1-6} alkyl, OC_{1-6}

₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein each C₁₋₆ alkyl, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

5 each R^B is independently hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein each C₁₋₆ alkyl, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

10 R^C is hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein the C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^D is hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein the C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^J is hydrogen, C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, wherein the C₁₋₆ alkyl, OC₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

bond (a) is a single or double bond;

n is 1 or 2; and t is 2;

with the provisos that:

25 (I) when Ring Q³ is an optionally substituted 5-membered aromatic heterocyclic ring, then R^{2a} is hydrogen, R^{2b} is hydrogen, R^{2c} is hydrogen, and R^{2d} is hydrogen; and

(II) when bond (a) is a double bond, then Z is C.

30 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q³ is a 5- or 6-membered aromatic heterocyclic ring;

wherein the 5- or 6-membered aromatic heterocyclic

ring is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, OC₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl;

wherein each C₁₋₆ alkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents;

wherein each OC₁₋₆ alkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and a saturated 4- to 8-membered heterocyclyl; and

wherein each C₃₋₁₀ cycloalkyl substituent of Ring Q³ is optionally and independently substituted with 1, 2, or 3 independently selected halogen substituents.


15

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is CH.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is N.

20

5. The compound according to claim 1, wherein the compound is of Formula (1a):



25 or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} is hydrogen or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is


optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1b} is hydrogen or C_{1-6} alkyl, wherein the C_{1-6} alkyl is optionally substituted with 1, 2, or 3 independently
5 selected halogen substituents;

R^{1c} is hydrogen or C_{1-6} alkyl, wherein the C_{1-6} alkyl is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{1d} is hydrogen or C_{1-6} alkyl, wherein the C_{1-6} alkyl is
10 optionally substituted with 1, 2, or 3 independently selected halogen substituents.

6. The compound according to claim 1, wherein the compound is of Formula (1b):




(1b)

15

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q1
20 is Formula (4a), Formula (4b), Formula (4c), or Formula (4e):



wherein:

R^{3a} is hydrogen, halogen, cyano, C₁₋₆ alkyl, NH₂, or OC₁₋₆ alkyl;

5 wherein the C₁₋₆ alkyl of R^{3a} is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

 wherein the NH₂ of R^{3a} is optionally substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents; and

10 wherein the OC₁₋₆ alkyl of R^{3a} is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

R^{3b} is hydrogen, halogen, cyano, C₁₋₆ alkyl, NH₂, or OC₁₋₆ alkyl;


 wherein the C₁₋₆ alkyl of R^{3b} is optionally substituted with 1, 2, or 3 independently selected halogen substituents;

 wherein the NH₂ of R^{3b} is optionally substituted with 1 or 2 independently selected C₁₋₆ alkyl substituents; and

 wherein the OC₁₋₆ alkyl of R^{3b} is optionally substituted with 1, 2, or 3 independently selected halogen substituents; and

~~~~~ is the point of attachment to V.

8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q<sup>1</sup> is Formula (5a), Formula (5b), Formula (5c), or Formula (5d):




wherein R<sup>4a</sup> is C<sub>1-6</sub> alkyl or OC<sub>1-6</sub> alkyl,

R<sup>4b</sup> is hydrogen or C<sub>1-6</sub> alkyl; and

~~~~~ is the point of attachment to V.

10


9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q² is Formula (3a):



15 wherein:

~~~~~ is the point of attachment to Z.

10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Q<sup>2</sup> is Formula (3b):



5 wherein:

~~~~~ is the point of attachment to Z.

11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

- 10 R^{1a} is hydrogen;
 R^{1b} is hydrogen;
 R^{1c} is hydrogen; and
 R^{1d} is hydrogen.

15 12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

- R^{2a} is hydrogen;
 R^{2b} is hydrogen;
 R^{2c} is hydrogen; and
 20 R^{2d} is hydrogen.

13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:




- each R^A is independently hydrogen; and
 25 each R^B is independently hydrogen.

14. The compound according to claim 1, or a


pharmaceutically acceptable salt thereof, wherein bond (a) is a single bond.

15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 2.

16. The compound according to claim 1, wherein the compound is selected from the group consisting of:






, and



or a pharmaceutically acceptable salt thereof.


17. The compound according to claim 1, wherein the
 5 compound is represented by any one of the following
 formulae:






or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 17, which is
5 represented by the following formula:




or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 17, which is
10 represented by the following formula:



or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 17, which is
15 represented by the following formula:



or a pharmaceutically acceptable salt thereof.

21. A drug comprising a compound according to claim 1, or
 5 a pharmaceutically acceptable salt thereof, as an active ingredient.

22. A medicament comprising a pharmaceutically acceptable
 excipient, at least one drug, and a compound according to
 10 claim 1, or a pharmaceutically acceptable salt thereof, as
 an active ingredient;

wherein each drug is independently selected from the
 group consisting of an adrenaline beta receptor antagonist,
 an analgesic drug, an anticonvulsant, an antidementia drug,
 15 an antidepressant drug, an antiemetic drug, an
 antiepileptic drug, an antimigraine drug, an
 antiparkinsonian drug, an antischizophrenic agent, an
 anxiolytic drug, a dopamine receptor agonist, a dopamine
 supplement, a hormone preparation, a drug for treating a
 20 mood disorder, and a sleep-inducing drug.

23. Use of the compound according to claim 1, or a
 pharmaceutically acceptable salt thereof, in the
 manufacture of a medicament for treating a central nervous
 25 system disease or disorder or a mental disease or disorder.

24. The use according to claim 23, wherein the central

nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of a behavioral disorder due to psychoactive substance use, a behavioral disorder with onset usually occurring in childhood, a behavioral disorder with onset usually occurring in adolescence, a degenerative disease of the central nervous system, a delusional disorder, an emotional disorder with onset usually occurring in childhood, an emotional disorder with onset usually occurring in adolescence, an extrapyramidal movement disorder, a mental disorder due to psychoactive substance use, a mood affective disorder, a neurotic disorder, an organic mental disorder, a pervasive developmental disorder, schizophrenia, a schizotypal disorder, sexual dysfunction not caused by an organic disorder or organic disease, a sleep disorder, a somatoform disorder, and a stress-related disorder.

25. The use according to claim 24, wherein the sleep disorder is a nonorganic sleep disorder.

20

26. The use according to claim 23, wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of aggression associated with Alzheimer's disease, agitation associated with Alzheimer's disease, a bipolar disorder with a psychotic feature, a depressive disorder with a psychotic feature, irritation associated with Alzheimer's disease, a negative symptom of schizophrenia, a positive symptom of schizophrenia, a psychopathic symptom associated with Alzheimer's disease, a psychopathic symptom associated with dementia, a psychopathic symptom associated with Parkinson's disease, and schizophrenia.

30

27. The use according to claim 26, wherein the psychopathic symptom associated with dementia is a psychopathic symptom associated with dementia with Lewy bodies.

5

28. The use according to claim 26, wherein the psychopathic symptom associated with Parkinson's disease is a psychopathic symptom associated with Parkinson's disease with dementia.

10

29. The use according to claim 23, wherein the central nervous system disease or disorder or the mental disease or disorder is selected from the group consisting of aggression associated with Alzheimer's disease, agitation associated with Alzheimer's disease, irritation associated with Alzheimer's disease, a psychopathic symptom associated with Alzheimer's disease, a psychopathic symptom associated with dementia, and schizophrenia.

30. The use according to claim 29, wherein the psychopathic symptom associated with dementia is a psychopathic symptom associated with dementia with Lewy bodies.

31. Use of at least one drug and the compound according to claim 1, or a pharmaceutically acceptable salt thereof, as an active ingredient in the manufacture of a medicament for treating a central nervous system disease or disorder or a mental disease or disorder,

wherein each drug is independently selected from the group consisting of an adrenaline beta receptor antagonist, an analgesic drug, an anticonvulsant, an antidementia drug, an antidepressant drug, an antiemetic drug, an

antiepileptic drug, an antimigraine drug, an
antiparkinsonian drug, an antischizophrenic agent, an
anxiolytic drug, a dopamine receptor agonist, a dopamine
supplement, a hormone preparation, a drug for treating a
5 mood disorder, and a sleep-inducing drug.

32. The use according to claim 31, wherein first the at
least one drug is to be administered to a patient, and
second the compound according to claim 1, or a
10 pharmaceutically acceptable salt thereof, is to be
administered to the patient.

33. The use according to claim 31, wherein first the
compound according to claim 1, or a pharmaceutically
15 acceptable salt thereof, is to be administered to a patient,
and second the at least one drug is to be administered to
the patient.

34. The use according to claim 31, wherein the at least
20 one drug and the compound according to claim 1, or a
pharmaceutically acceptable salt thereof, are to be
administered to a patient concurrently.

35. Use of a pharmaceutically acceptable excipient, at
25 least one drug, and a compound according to claim 1, or a
pharmaceutically acceptable salt thereof, as an active
ingredient in the manufacture of a medicament for treating
a central nervous system disease or disorder or a mental
disease or disorder,

30 wherein each drug is independently selected from the
group consisting of an adrenaline beta receptor antagonist,
an analgesic drug, an anticonvulsant, an antidementia drug,
an antidepressant drug, an antiemetic drug, an

antiepileptic drug, an antimigraine drug, an
antiparkinsonian drug, an antischizophrenic agent, an
anxiolytic drug, a dopamine receptor agonist, a dopamine
supplement, a hormone preparation, a drug for treating a
5 mood disorder, and a sleep-inducing drug.